Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency

被引:57
作者
Razvi, S
Schneider, L
Jonas, MM
Cunningham-Rundles, C
机构
[1] CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA
[2] Harvard Univ, Sch Publ Hlth, Childrens Hosp, Boston, MA 02115 USA
关键词
D O I
10.1006/clim.2001.5132
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Physicians in the United States who treat patients with primary immunodeficiency were contacted to identify subjects who had been infected with hepatitis C due to exposure to contaminated intravenous immunoglobulin (IVIg) in 1993-1994. From this survey we gathered information on 58 PGR-positive hepatitis C- infected patients; 37 had CVID, 9 had XLA, 5 were IgG subclass deficient, 4 were antibody deficient with normal immunoglobulin levels, 2 had SCID after BMT, and 1 had B cell linker deficiency. Of the 58 subjects, 30 had been treated with IFN-a in combination with ribavirin in 5 cases, and 26 other subjects were not treated., Of those who were treated, 11 (37%) resolved the infection and became PCR-negative; of the 26 who were not treated, 5 (19%) have resolved the infection, outcomes not significantly different. Patients 20 years of age or younger had a significantly better outcome compared to those older than age 20 (P = 0.02). Five subjects of the 58 have had a liver transplantation, a sixth has had two transplants, and 10 (17%) of the group have died., This survey demonstrates the heterogeneity of the, clinical outcome in subjects with primary immunodeficiency who contracted hepatitis C due to viral contamination of IVIg. (C) 2001 Elsevier Science.
引用
收藏
页码:284 / 288
页数:5
相关论文
共 30 条
[11]   Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis [J].
Gramenzi, A ;
Andreone, P ;
Fiorino, S ;
Cammà, C ;
Giunta, M ;
Magalotti, D ;
Cursaro, C ;
Calabrese, C ;
Arienti, V ;
Rossi, C ;
Di Febo, G ;
Zoli, M ;
Craxi, A ;
Gasbarrini, G ;
Bernardi, M .
GUT, 2001, 48 (06) :843-848
[12]   Outbreak of acute hepatitis C following the use of anti-hepatitis C virus - Screened intravenous immunoglobulin therapy [J].
Healey, CJ ;
Sabharwal, NK ;
Daub, J ;
Davidson, F ;
Yap, PL ;
Fleming, KA ;
Chapman, RWG ;
Simmonds, P ;
Chapel, H .
GASTROENTEROLOGY, 1996, 110 (04) :1120-1126
[13]   Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis [J].
Heathcote, EJ ;
Shiffman, ML ;
Cooksley, WGE ;
Dusheiko, GM ;
Lee, SS ;
Balart, L ;
Reindollar, R ;
Reddy, RK ;
Wright, TL ;
Lin, A ;
Hoffman, J ;
De Pamphilis, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23) :1673-1680
[14]   Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection [J].
Hu, KQ ;
Vierling, JM ;
Redeker, AG .
JOURNAL OF VIRAL HEPATITIS, 2001, 8 (01) :1-18
[15]  
Jonas MM, 1996, PEDIATRICS, V98, P211
[16]  
LANE RS, 1983, LANCET, V2, P974
[17]  
LEVER AM, 1990, LANCET, V336, P1062
[18]   Current treatment strategies for chronic hepatitis B and C [J].
Lin, OS ;
Keeffe, EB .
ANNUAL REVIEW OF MEDICINE, 2001, 52 :29-49
[19]   An essential role for BLNK in human B cell development [J].
Minegishi, Y ;
Rohrer, J ;
Coustan-Smith, E ;
Lederman, HM ;
Pappu, R ;
Campana, D ;
Chan, AC ;
Conley, ME .
SCIENCE, 1999, 286 (5446) :1954-1957
[20]  
Munoz F J, 1995, Allergol Immunopathol (Madr), V23, P263